Search

Royalty Pharma PLC (Class A)

Avatud

SektorTervishoid

59.04 0.8

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

57.99

Max

59.13

Põhinäitajad

By Trading Economics

Sissetulek

-61M

295M

Müük

8.6M

631M

P/E

Sektori keskmine

30.639

62.58

Aktsiakasum

1.3

Dividenditootlus

1.54

Kasumimarginaal

46.733

Töötajad

100

EBITDA

112M

563M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+6.81% upside

Dividendid

By Acuity

Dividenditootlus

Sektori keskmine

1.54%

2.19%

Järgmine tulemuste avaldamine

5. aug 2026

Järgmine dividendimakse kuupäev

10. sept 2026

Järgmine aktsia dividendi kuupäev (ex-date)

14. aug 2026

Turustatistika

By TradingEconomics

Turukapital

3.2B

33B

Eelmine avamishind

58.24

Eelmine sulgemishind

59.04

Uudiste sentiment

By Acuity

50%

50%

144 / 340 Pingereas Healthcare

Royalty Pharma PLC (Class A) Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

22. juuli 2026, 19:11 UTC

News
Event

Royalty Pharma acquires a royalty interest in AstraZeneca's cliramitug for up to $425 million, including $125 million upfront payment. Shares are trading roughly flat.

21. juuli 2026, 17:51 UTC

Royalty Pharma PLC shares are higher today, tracking broader market gains, with unusually high trading volume noted. No specific news was identified for the movement.

20. juuli 2026, 19:21 UTC

Royalty Pharma PLC shares are lower as the Pharmaceuticals sector faces downward pressure, with unusually high trading volume noted today.

Võrdlus sarnastega

Hinnamuutus

Royalty Pharma PLC (Class A) Prognoos

Hinnasiht

By TipRanks

6.81% tõus

12 kuu keskmine prognoos

Keskmine 62.4 USD  6.81%

Kõrge 66 USD

Madal 58 USD

Põhineb 6 Wall Streeti analüütiku instrumendi Royalty Pharma PLC (Class A) 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

6 ratings

6

Osta

0

Hoia

0

Müü

Sentiment

By Acuity

144 / 340 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Keskmine

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Royalty Pharma PLC (Class A)

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
help-icon Live chat